Artelo Biosciences (ARTL) to Release Earnings on Monday

Artelo Biosciences (NASDAQ:ARTL) is projected to post its quarterly earnings results before the market opens on Monday, March 24th. Analysts expect Artelo Biosciences to post earnings of ($0.74) per share for the quarter.

Artelo Biosciences (NASDAQ:ARTL) last posted its quarterly earnings data on Monday, March 3rd. The company reported ($1.17) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.74) by ($0.43). On average, analysts expect Artelo Biosciences to post $-3 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Artelo Biosciences Price Performance

Shares of NASDAQ:ARTL opened at $1.04 on Friday. Artelo Biosciences has a 1-year low of $0.91 and a 1-year high of $1.60. The company has a market capitalization of $3.41 million, a P/E ratio of -0.36 and a beta of 1.06. The firm’s 50 day simple moving average is $1.14 and its two-hundred day simple moving average is $1.13.

Wall Street Analysts Forecast Growth

Several research firms have recently issued reports on ARTL. D. Boral Capital reiterated a “buy” rating and set a $6.00 price objective on shares of Artelo Biosciences in a research report on Thursday, February 27th. LADENBURG THALM/SH SH upgraded shares of Artelo Biosciences to a “strong-buy” rating in a research report on Wednesday, December 25th. Finally, HC Wainwright restated a “buy” rating and issued a $5.00 price target on shares of Artelo Biosciences in a research report on Tuesday, March 4th.

Artelo Biosciences Company Profile

Artelo Biosciences, Inc, a clinical stage biopharmaceutical company, develops and commercializes therapeutics that target lipid-signaling pathways in the United States. It's product candidate pipeline includes ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal for the treatment anxiety, post-traumatic stress disorder, epilepsy, inflammatory bowel disease, and other potential indications; and ART26.12, a fatty acid binding protein 5 inhibitor for treating chemotherapy induced peripheral neuropathy, diabetic neuropathy, prostate cancer and breast cancer, pain, dermatologic conditions, and anxiety disorders.